Tag: GPT5

Browse our exclusive articles!

Investor Frenzy Over Short-Term AI Gains in Silicon Valley is Too Much, Says OpenAI CEO Sam Altman

OpenAI CEO Sam Altman warns Silicon Valley investors that there is too much hype surrounding the short-term value of AI technology. Although the long-term potential is underhyped, Altman states that much work needs to be done before they can start the model. Despite this, the company recently raised $495 million in funding and is valued at $27-29 billion.

Why Open AI CEO Sal Altman Delays GPT-5 Training

OpenAI CEO Sam Altman confirms GPT-5 won't receive training yet due to extensive required work. Expected release in 2024 with improved functionality. Altman emphasizes the importance of lawmakers' involvement in AI regulation.

AI Regulations Should Not Apply to Smaller Startups, Says OpenAI CEO Sam Altman

OpenAI CEO Sam Altman suggests that only larger companies, including OpenAI itself, should face AI regulations. Altman stressed the need for nuanced discussions around AI while acknowledging concerns about its darker aspects. He also believes that AI is under-hyped in the long term and OpenAI is not yet training GPT5. Read more to understand his perspective.

Why GPT-5 is Unlikely to be Developed Anytime Soon: Six Reasons

OpenAI CEO reveals scaling setbacks and GPU limitations are delaying GPT-5's release, with only a modest size increase from GPT-4 expected.

Sam Altman: Bigger Isn’t Always Better – A Shift in AI Development According to OpenAI

OpenAI, founded by Elon Musk and other top AI experts, shifts focus away from larger models to developing the most capable, useful and safe models for the commercial market. Sam Altman, OpenAI's CEO, highlights the need for responsible development and critique of emerging tech and AI. Be it GPT-4, GPT-5 or ChatGPT, OpenAI stands at the forefront of critical discussions to ensure the impact of rapidly evolving AI technologies.

Popular

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.

Pioneering Research Uncovers Vital Biomarker for Orbital Inflammation

An in-depth study reveals HLF as a potential biomarker for orbital inflammation, offering new insights for diagnosis and treatment strategies.

Subscribe

spot_imgspot_img